Table 3.
Results of infectious screening assays (stool)
| Infectious agent | Assay | Pre-COVID Donors | Pre-COVID Recipients | Post-COVID Donors | Post-COVID Recipients | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seropositive rate | Seronegative rate | n | Seropositive rate | Seronegative rate | n | Seropositive rate | Seronegative rate | n | Seropositive rate | Seronegative rate | n | ||
| Stool | |||||||||||||
| Campylobacter species | GI pathogen panel | 0% | 100% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Clostridium difficile (C. diff) | C. diff toxin with reflex PCR | 7.1% | 92.9% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Escherichia coli O157:H7 | E. coli O157:H7 | 0% | 100% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Helicobacter pylori (H. pylori) | H. pylori antigen with reflex ELISA | 0% | 100% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Salmonella | GI pathogen panel | 0% | 100% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Shigella | GI pathogen panel | 0% | 100% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Vibrio | GI pathogen panel | 0% | 100% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Yersinia | GI pathogen panel | 0% | 100% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| vRotavirus | GI pathogen panel | 0% | 100% | 28 | 5.9% | 94.1% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Adenovirus | Adenovirus DNA PCR | 0% | 100% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Norovirus | GI pathogen panel | 3.6% | 96.4% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Giardia | Ova and parasite screen | 0% | 100% | 28 | 0% | 100% | 17 | 3.7% | 96.3% | 27 | 0% | 100% | 1 |
| Cryptosporidia | Ova and parasite screen | 0% | 100% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Vancomycin-resistant Enterococcus (VRE) | VRE screen | 0% | 100% | 28 | 0% | 100% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Carbapenem-resistant Enterobacteriaceae (CRE) | CRE screen | 0% | 100% | 28 | 5.9% | 94.1% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL) | ESBL screen | 0% | 100% | 28 | 5.9% | 94.1% | 17 | 0% | 100% | 27 | 0% | 100% | 1 |
| SARS-CoV-2 | COVID-19 rtPCR | N/A | N/A | N/A | N/A | N/A | N/A | 11.1% | 88.9% | 27 | 0% | 100% | 1 |